Andrew Huberman· PhD
And so, you know, we have over the last couple of years been able to do this first in human, kind of full neurobiological clinical neurocognitive evaluation of what ibogaine is doing... And so we've been able to capture all the clinical scales, you know, depression scales, PTSD scales, all that standard stuff, neurocognitive batteries... And so, you know, we have over the last couple of years been able to do this first in human, kind of full neurobiological clinical neurocognitive evaluation of what ibogaine is doing. In this case, in special operations, special forces individuals, former Navy SEALs, former Army Rangers, that kind of crew of folks, and look at the pre-post changes that their experience to be able to totally quantitate all of that. And so we've been able to capture all the clinical scales, you know, depression scales, PTSD scales, all that standard stuff, neurocognitive batteries. So how does your executive function work specifically? How does your verbal memory, all of that? And then neuroimaging and EEG. So this will be the first human study of ibogaine for those. And the reason why is because ibogaine is kind of the... Both seemingly the most potent and most seemingly, to me at least, most powerful psychedelic, but the one that has the most risk too, because it has a cardiac effect. It seems to be that you can screen people out that have risk off of their electrocardiogram and reduce the risk quite a bit. And that's what we all did. But that's why people haven't really studied it as much. And it isn't as, in addition, nobody goes to a rave on ibogaine. There's no recreation at all with this. - It's not fun. - It's, people say that it's relieving, but it's hard work, right? Because yeah, you're reexamining things. And you know, and so then we see these folks after, and I'll tell you, you know, we haven't fully analyzed the data yet, but I'll tell you that, you know, from what my folks are telling me, it's pretty dramatic. You know, people come back and they're doing a lot better. They're doing a lot better. And nobody, I'll knock on wood, nobody's had any sort of cardiac issue at all in the cohort that we've studied and they look a lot better and they feel a lot better too.